(0.10%) 5 159.75 points
(0.09%) 38 868 points
(0.03%) 18 007 points
(0.92%) $78.83
(-0.19%) $2.14
(0.93%) $2 330.00
(2.51%) $27.36
(0.50%) $970.15
(-0.02%) $0.929
(-0.27%) $10.85
(-0.20%) $0.795
(0.12%) $91.56
Quarter results tomorrow
(bmo 2024-05-07)
Expected move: +/- 18.00%
@ $1.110
发出时间: 14 Feb 2024 @ 22:32
回报率: 4.50%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 2.30 %
Live Chart Being Loaded With Signals
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease...
Stats | |
---|---|
今日成交量 | 4.46M |
平均成交量 | 4.47M |
市值 | 175.17M |
EPS | $0 ( 2024-03-05 ) |
下一个收益日期 | ( $0 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.300 |
ATR14 | $0.00700 (0.61%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Graves Kurt | Buy | 60 000 | Stock Option (right to buy) |
2024-04-04 | Kender Richard N | Buy | 60 000 | Stock Option (right to buy) |
2024-04-04 | Biondi Paul | Buy | 60 000 | Stock Option (Right to Buy) |
2024-04-04 | Fraser Claire | Buy | 60 000 | Stock Option (right to buy |
2024-04-04 | Dere Willard H | Buy | 60 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
92.37 |
Last 99 transactions |
Buy: 7 007 921 | Sell: 289 369 |
音量 相关性
Seres Therapeutics Inc 相关性 - 货币/商品
Seres Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $126.33M |
毛利润: | $111.21M (88.04 %) |
EPS: | $-0.890 |
FY | 2023 |
营收: | $126.33M |
毛利润: | $111.21M (88.04 %) |
EPS: | $-0.890 |
FY | 2022 |
营收: | $7.13M |
毛利润: | $6.12M (85.91 %) |
EPS: | $-2.35 |
FY | 2021 |
营收: | $144.93M |
毛利润: | $144.93M (100.00 %) |
EPS: | $-0.720 |
Financial Reports:
No articles found.
Seres Therapeutics Inc
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。